narmafotinib + chemotherapy

narmafotinib + chemotherapy is an investigational combination therapy being developed by Amplia Therapeutics for the treatment of advanced solid tumors, particularly pancreatic cancer and ovarian cancer. Narmafotinib (formerly AMP945) is a highly potent, selective, and orally bioavailable small molecule inhibitor of Focal Adhesion Kinase (FAK). FAK is a non-receptor tyrosine kinase that is frequently overexpressed in pancreatic and other cancers, where it promotes tumor cell survival, migration, and the development of a dense, fibrotic extracellular matrix (stroma) that acts as a physical barrier to chemotherapy delivery. By inhibiting FAK, narmafotinib primes the tumor microenvironment, reducing stromal stiffness and density, thereby enhancing the penetration and efficacy of co-administered standard-of-care chemotherapies. In clinical development, narmafotinib is being evaluated in combination with gemcitabine and nab-paclitaxel (Abraxane) or FOLFIRINOX in Phase 1b/2 trials (such as the ACCENT and AMPLICITY trials) for advanced pancreatic cancer, and is planned for evaluation in ovarian cancer (PRROSE trial).

Other names

AMP945 + FOLFIRINOXAMP945 + chemotherapyAMP945 + gemcitabine + AbraxaneAMP945 + gemcitabine + nab-paclitaxelnarmafotinib + FOLFIRINOXnarmafotinib + gemcitabine + Abraxanenarmafotinib + gemcitabine + nab-paclitaxel